SCHEMBL6421166

SCHEMBL6421166

CCOC(=O)c1cc(COC(=O)c2ccccc2)nn1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
GAA P10253 1/20 0.56
LMNA P02545 2/20 0.51
ALDH1A1 P00352 5/20 0.50
MAPT P10636 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
POLB P06746 2/20 0.50
KDM4E B2RXH2 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
PDE4D Q08499 1/20 0.50
HPGD P15428 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
TP53 P04637 3/20 0.47
MEN1 O00255 2/20 0.47
ALOX12 P18054 2/20 0.47
THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22896894 0.86 LMNA (0.56) KMT2AGAALMNAALDH1A1MAPT
SCHEMBL6414424 0.85 LMNA (0.51) KMT2AGAALMNAALDH1A1MAPT
SCHEMBL6419868 0.85 LMNA (0.51) KMT2AGAALMNAALDH1A1MAPT
SCHEMBL6415169 0.85 LMNA (0.55) KMT2AGAALMNAALDH1A1MAPT
SCHEMBL6415836 0.84 LMNA (0.50) KMT2AGAALMNAALDH1A1MAPT
SCHEMBL6415533 0.84 LMNA (0.54) KMT2AGAALMNAALDH1A1MAPT
SCHEMBL16142903 0.82 ALDH1A1 (0.54) KMT2AGAALMNAALDH1A1MAPT
SCHEMBL6415508 0.82 LMNA (0.48) KMT2AGAALMNAALDH1A1MAPT
SCHEMBL6419934 0.81 ALDH1A1 (0.52) KMT2AGAALMNAALDH1A1POLB
SCHEMBL6422295 0.80 KMT2A (0.65) KMT2AGAALMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AHR, NQO1, ARNT KMT2A 1284/4885GAA 1397/4885LMNA 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.